IS7043A - Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu - Google Patents

Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu

Info

Publication number
IS7043A
IS7043A IS7043A IS7043A IS7043A IS 7043 A IS7043 A IS 7043A IS 7043 A IS7043 A IS 7043A IS 7043 A IS7043 A IS 7043A IS 7043 A IS7043 A IS 7043A
Authority
IS
Iceland
Prior art keywords
lungs
administration
chemically transformed
insulin
transformed insulin
Prior art date
Application number
IS7043A
Other languages
English (en)
Inventor
S. Patton John
Kuo Mei-Chang
Milton Harris J.
Leach Chester
Perkins Kimberly
Bueche Blaine
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of IS7043A publication Critical patent/IS7043A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
IS7043A 2001-05-21 2003-11-19 Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu IS7043A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29242301P 2001-05-21 2001-05-21
PCT/US2002/016464 WO2002094200A2 (en) 2001-05-21 2002-05-21 Pulmonary administration of chemically modified insulin

Publications (1)

Publication Number Publication Date
IS7043A true IS7043A (is) 2003-11-19

Family

ID=23124608

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7043A IS7043A (is) 2001-05-21 2003-11-19 Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu

Country Status (35)

Country Link
US (3) US6838076B2 (is)
EP (1) EP1395294A4 (is)
JP (1) JP2004535401A (is)
KR (1) KR20030097876A (is)
CN (2) CN101045166A (is)
AP (1) AP1763A (is)
AR (1) AR033903A1 (is)
AU (1) AU2002303869B2 (is)
BG (1) BG108494A (is)
BR (1) BR0209896A (is)
CA (1) CA2447236A1 (is)
CO (1) CO5540371A2 (is)
CZ (1) CZ20033182A3 (is)
EA (1) EA007408B1 (is)
EC (1) ECSP034855A (is)
GE (1) GEP20063917B (is)
HR (1) HRP20030949A2 (is)
HU (1) HUP0400442A2 (is)
IL (2) IL158862A0 (is)
IS (1) IS7043A (is)
LT (1) LT5153B (is)
LV (1) LV13197B (is)
MA (1) MA26185A1 (is)
MX (1) MXPA03010649A (is)
MY (1) MY137181A (is)
NO (1) NO20035157D0 (is)
NZ (1) NZ529572A (is)
OA (1) OA13136A (is)
PL (1) PL366911A1 (is)
SK (1) SK15532003A3 (is)
TN (1) TNSN03116A1 (is)
TR (1) TR200400295T2 (is)
WO (1) WO2002094200A2 (is)
YU (1) YU98503A (is)
ZA (1) ZA200309085B (is)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
OA13136A (en) * 2001-05-21 2006-12-13 Nektar Therapeutics Pulmonary administration of chemically modified insulin.
NZ519403A (en) * 2001-06-21 2005-03-24 Pfizer Prod Inc Use of insulin in a medicament to reduce weight gain in a diabetic patient who is using exogenous insulin to control blood sugar levels
WO2003059317A2 (en) * 2001-12-21 2003-07-24 3M Innovative Properties Company Medicinal aerosol compositions with a functionalized polyethyleneglycol excipient
PT1494732E (pt) 2002-03-20 2008-03-20 Mannkind Corp Aparelho de inalação
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
CN102139114A (zh) * 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
WO2004091494A2 (en) * 2003-04-11 2004-10-28 Pr Pharmaceuticals Inc. Method for preparation of site-specific protein conjugates
EP1491554A1 (en) * 2003-06-23 2004-12-29 CONARIS research institute AG PEGylated soluble gp130-dimers useful as a medicament
ES2447423T3 (es) * 2003-08-29 2014-03-12 Dyax Corp. Inhibidores de proteasa poli-pegilados
WO2005021556A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
GB0328629D0 (en) * 2003-12-10 2004-01-14 Medpharm Ltd Metered dose inhalation preparations
JP2008505853A (ja) 2004-04-13 2008-02-28 クインテセンス バイオサイエンシーズ インコーポレーティッド 細胞傷害性薬剤としての非天然のリボヌクレアーゼ複合体
PL2626368T3 (pl) 2004-07-19 2017-06-30 Biocon Limited Koniugaty insulina-oligomer, ich formulacje i zastosowania
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
PL2322180T3 (pl) 2004-08-23 2015-10-30 Mannkind Corp Sole diketopiperazyny do dostarczania leków
US20060046852A1 (en) * 2004-08-26 2006-03-02 Rowe Richard E Wide area gaming system
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US8245758B2 (en) * 2006-10-30 2012-08-21 GM Global Technology Operations LLC Coulomb damped disc brake rotor and method of manufacturing
US20080206342A1 (en) * 2005-01-10 2008-08-28 Rosemary Kovelesky Compositions and Methods For Increasing the Bioavailability of Pulmonarily Administered Insulin
EP1843790A2 (en) * 2005-01-27 2007-10-17 Novo Nordisk A/S Insulin derivatives conjugated with structurally well defined branched polymers
TWI376234B (en) * 2005-02-01 2012-11-11 Msd Oss Bv Conjugates of a polypeptide and an oligosaccharide
ES2438145T3 (es) 2005-02-02 2014-01-16 Novo Nordisk A/S Nuevos derivados de insulina
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
WO2006097521A1 (en) * 2005-03-18 2006-09-21 Novo Nordisk A/S Pegylated single-chain insulin
US20060271011A1 (en) * 2005-05-25 2006-11-30 Mock Bradley D Methods and apparatus for indicating when a disposable component of a drug delivery system needs to be replaced
ES2555310T3 (es) 2005-09-14 2015-12-30 Mannkind Corporation Método de formulación de fármacos basado en el incremento de la afinidad de superficies de micropartículas cristalinas por principios activos
US8168592B2 (en) * 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US7827042B2 (en) * 2005-11-30 2010-11-02 The Invention Science Fund I, Inc Methods and systems related to transmission of nutraceutical associated information
US10296720B2 (en) * 2005-11-30 2019-05-21 Gearbox Llc Computational systems and methods related to nutraceuticals
US20110145009A1 (en) * 2005-11-30 2011-06-16 Jung Edward K Y Methods and systems related to transmission of nutraceutical associatd information
US20080052114A1 (en) * 2005-11-30 2008-02-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational systems and methods related to nutraceuticals
US8297028B2 (en) 2006-06-14 2012-10-30 The Invention Science Fund I, Llc Individualized pharmaceutical selection and packaging
US20070136092A1 (en) * 2005-11-30 2007-06-14 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20080004905A1 (en) * 2006-06-28 2008-01-03 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems for analysis of nutraceutical associated components
US8340944B2 (en) * 2005-11-30 2012-12-25 The Invention Science Fund I, Llc Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US7927787B2 (en) * 2006-06-28 2011-04-19 The Invention Science Fund I, Llc Methods and systems for analysis of nutraceutical associated components
US7974856B2 (en) 2005-11-30 2011-07-05 The Invention Science Fund I, Llc Computational systems and methods related to nutraceuticals
US20080033763A1 (en) * 2005-11-30 2008-02-07 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Methods and systems related to receiving nutraceutical associated information
US20070289258A1 (en) * 2006-06-14 2007-12-20 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Individualized pharmaceutical selection and packaging
US20080114577A1 (en) * 2005-11-30 2008-05-15 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational methods and systems associated with nutraceutical related assays
US20080103746A1 (en) * 2005-11-30 2008-05-01 Searete Llc, A Limited Liability Corporation Systems and methods for pathogen detection and response
US20070174128A1 (en) * 2005-11-30 2007-07-26 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized pharmaceutical and nutraceutical selection and packaging
US20070124218A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems related to individualized nutraceutical selection and packaging
US20070124176A1 (en) * 2005-11-30 2007-05-31 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Computational and/or control systems and methods related to nutraceutical agent selection and dosing
US8000981B2 (en) 2005-11-30 2011-08-16 The Invention Science Fund I, Llc Methods and systems related to receiving nutraceutical associated information
CA2841386A1 (en) * 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
CA2643464C (en) * 2006-02-22 2018-09-04 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US20070292404A1 (en) * 2006-03-27 2007-12-20 Biosynexus Incorporated Antimicrobial polymer conjugates
WO2007149594A2 (en) 2006-06-23 2007-12-27 Quintessence Biosciences, Inc. Modified ribonucleases
RS51544B (en) * 2006-06-30 2011-06-30 Conaris Research Institute Ag. POBOLJŠANI SGP 130FC DIMERI
US8298801B2 (en) 2006-07-17 2012-10-30 Quintessence Biosciences, Inc. Methods and compositions for the treatment of cancer
WO2008015099A2 (en) * 2006-07-31 2008-02-07 Novo Nordisk A/S Pegylated, extended insulins
US20090208480A1 (en) * 2006-08-04 2009-08-20 Yue Huang Long half-life recombinant butyrylcholinesterase
HUE029512T2 (en) 2006-09-22 2017-03-28 Novo Nordisk As Protease Resistant Insulin Analogs
WO2008067158A2 (en) 2006-11-13 2008-06-05 Auxagen, Inc. METHOD TO PROMOTE HAIR GROWTH AND/OR DELAY OR TREAT HAIR LOSS BY ADMINISTERING A TGF-β ANTAGONIST OR INHIBITOR
WO2008084051A1 (en) * 2007-01-12 2008-07-17 Novo Nordisk A/S Mixtures of pegylated insulin and fast acting insulin for pulmonary administration
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
JP5615558B2 (ja) * 2007-02-28 2014-10-29 セリナ・セラピユーテイツクス・インコーポレーテツド 活性ポリオキサゾリンおよびそれを含む組成物
EP2502618A3 (en) 2007-04-30 2012-10-03 Novo Nordisk A/S Method for drying a protein composition, a dried protein composition and a pharmaceutical composition comprising the dried protein
WO2009020434A1 (en) * 2007-08-07 2009-02-12 Nanomaterials Technology Pte Ltd A process for making micro-sized protein particles
CA2699454C (en) * 2007-08-27 2012-07-24 Auxagen, Inc. Methods for inhibiting tgf-.beta.
US8697062B2 (en) * 2007-10-08 2014-04-15 Quintessence Biosciences, Inc. Compositions and methods for ribonuclease-based therapeutics
WO2009050738A2 (en) 2007-10-16 2009-04-23 Biocon Limited An orally administerable solid pharmaceutical composition and a process thereof
WO2009065126A2 (en) * 2007-11-16 2009-05-22 Boston Protein Solutions Excipients for protein stabilization
ES2618073T3 (es) 2008-03-14 2017-06-20 Novo Nordisk A/S Análogos de insulina estabilizados frente a proteasas
WO2009115469A1 (en) 2008-03-18 2009-09-24 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
JP5421362B2 (ja) 2008-06-13 2014-02-19 マンカインド コーポレイション 薬物送達用の乾燥粉末吸入器およびシステム
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8488661B2 (en) * 2008-06-13 2013-07-16 Verizon Patent And Licensing Inc. Systems and methods for data streaming
DK2300083T3 (da) 2008-06-20 2013-07-22 Mannkind Corp Interaktivt apparat og fremgangsmåde til realtids-profilering af inhalationsforsøg
TWI614024B (zh) 2008-08-11 2018-02-11 曼凱公司 超快起作用胰島素之用途
US8487006B2 (en) * 2008-09-16 2013-07-16 Auxagen, Inc. Method of enhancing TGF-β signalling
JP5765813B2 (ja) * 2008-09-19 2015-08-19 ウェルズ ファーゴ バンク ナショナル アソシエイション 治療用ペプチドのポリマーコンジュゲート
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
EP2334695B1 (en) 2008-10-01 2015-12-23 Quintessence Biosciences, Inc. Therapeutic ribonucleases
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2379511B1 (en) 2008-12-29 2014-12-17 MannKind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
CN102307594A (zh) 2009-01-06 2012-01-04 戴埃克斯有限公司 用激肽释放酶抑制剂治疗粘膜炎
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
KR20180079458A (ko) 2009-06-12 2018-07-10 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
ES2636741T3 (es) 2009-07-31 2017-10-09 Sanofi-Aventis Deutschland Gmbh Composición de insulina de acción prolongada
MA33467B1 (fr) 2009-07-31 2012-07-03 Sanofi Aventis Deutschland Promédicaments comprenant un conjugué insuline-lieur
EP2488172A4 (en) 2009-10-13 2014-08-13 Univ Michigan DENDRIMER COMPOSITION AND METHOD FOR THEIR SYNTHESIS
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
CA2784861A1 (en) 2009-12-21 2011-07-14 Pharmathene, Inc. Recombinant butyrylcholinesterases and truncates thereof
PL3459564T3 (pl) 2010-01-06 2022-04-19 Takeda Pharmaceutical Company Limited Białka wiążące kalikreinę osocza
AR081066A1 (es) 2010-04-02 2012-06-06 Hanmi Holdings Co Ltd Conjugado de insulina donde se usa un fragmento de inmunoglobulina
US9981017B2 (en) 2010-04-02 2018-05-29 Hanmi Science Co., Ltd. Insulin conjugate using an immunoglobulin fragment
RU2531455C2 (ru) 2010-06-21 2014-10-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
KR102011156B1 (ko) 2011-01-06 2019-08-16 다이액스 코포레이션 혈장 칼리크레인 결합 단백질
EP2686003A2 (en) 2011-03-15 2014-01-22 Novo Nordisk A/S Human insulin analogues and derivatives comprising cysteine substitutions
CN102675452B (zh) 2011-03-17 2015-09-16 重庆富进生物医药有限公司 具持续降血糖和受体高结合的人胰岛素及类似物的偶联物
JP6133270B2 (ja) 2011-04-01 2017-05-24 マンカインド コーポレイション 薬剤カートリッジのためのブリスター包装
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
IN2014DN03093A (is) 2011-10-24 2015-05-15 Mannkind Corp
CN102504022A (zh) * 2011-11-30 2012-06-20 苏州元基生物技术有限公司 含有保护赖氨酸的胰岛素原及使用其制备胰岛素的方法
JP6199956B2 (ja) 2012-04-11 2017-09-20 ノヴォ ノルディスク アー／エス インスリン製剤
US9457096B2 (en) 2012-07-06 2016-10-04 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Concet) Protozoan variant-specific surface proteins (VSP) as carriers for oral drug delivery
JP6312262B2 (ja) 2012-07-12 2018-04-18 マンカインド コーポレイション 乾燥粉末薬物送達システム
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
EP2925345B1 (en) 2012-12-03 2018-09-05 Merck Sharp & Dohme Corp. Method for making o-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
WO2015010092A1 (en) 2013-07-18 2015-01-22 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
CA2924109A1 (en) 2013-09-13 2015-03-19 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
HUE036702T2 (hu) 2013-10-07 2018-07-30 Novo Nordisk As Inzulinanalóg új származéka
KR102455171B1 (ko) 2013-12-18 2022-10-14 더 스크립스 리서치 인스티튜트 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
CA2969301A1 (en) 2014-12-01 2016-06-09 Ferring B.V. Administration of a selective il-6-trans-signalling inhibitor
MA41116A (fr) 2014-12-01 2017-10-10 Ferring Bv Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
EP3442998A4 (en) 2016-04-12 2020-04-01 Cell And Molecular Tissue Engineering, LLC SYSTEMS, METHODS AND PRODUCTS TO MINIMIZE TISSUE REACTIONS AND TISSUE INJURY AT AN INFUSION SITE
CN109952116B (zh) * 2016-11-02 2021-02-09 陶氏环球技术有限责任公司 固体非水性凝胶空气增香剂
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4652548A (en) 1981-08-27 1987-03-24 Eli Lilly And Company Pharmaceutical formulations comprising human insulin, human C-peptide, and human proinsulin
US4654324A (en) 1981-08-27 1987-03-31 Eli Lilly And Company Human proinsulin pharmaceutical formulations
DOP1982004086A (es) 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
EP0400472B1 (en) 1989-05-27 1996-04-03 Sumitomo Pharmaceuticals Company, Limited Process for preparing polyethylene glycol derivatives and modified protein.
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5681811A (en) * 1993-05-10 1997-10-28 Protein Delivery, Inc. Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
EP0761683B1 (en) * 1994-05-20 2005-02-02 Hisamitsu Pharmaceutical Co., Inc. Protein or polypeptide, process for producing the same, and intermediate compound tehrefor
US5730990A (en) * 1994-06-24 1998-03-24 Enzon, Inc. Non-antigenic amine derived polymers and polymer conjugates
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
DE19628143A1 (de) 1996-07-12 1998-01-15 Basf Ag Verfahren zur Herstellung einer wäßrigen Polymerisatdispersion
JP2001508783A (ja) 1997-01-29 2001-07-03 ポリマスク・ファーマシューティカルズ・パブリック・リミテッド・カンパニー Ｐｅｇ化法
IL135400A0 (en) 1997-10-24 2001-05-20 Novo Nordisk As Aggregates of human insulin derivatives
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
TR200100922T2 (tr) 1998-07-27 2001-09-21 Emisphere Technologies Inc. Aktif maddelerin akciğerler yolu ile tatbik edilmesi.
JP2002531518A (ja) * 1998-12-04 2002-09-24 プロヴァリス・ユーケー・リミテッド インスリン含有医薬組成物
EP1146860A4 (en) 1999-01-08 2002-07-03 Emisphere Tech Inc POLYMER DRUG DELIVERY SYSTEMS AND COMPOUNDS
US7169889B1 (en) * 1999-06-19 2007-01-30 Biocon Limited Insulin prodrugs hydrolyzable in vivo to yield peglylated insulin
US6309633B1 (en) 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
US6323311B1 (en) * 1999-09-22 2001-11-27 University Of Utah Research Foundation Synthesis of insulin derivatives
WO2001068141A2 (en) 2000-03-17 2001-09-20 Maxygen Aps Dispersions of polypeptide conjugates
WO2002092147A2 (en) * 2001-05-11 2002-11-21 Aradigm Corporation Optimization of the molecular properties and formulation of proteins delivered by inhalation
OA13136A (en) * 2001-05-21 2006-12-13 Nektar Therapeutics Pulmonary administration of chemically modified insulin.
US6828297B2 (en) 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
ES2307779T3 (es) * 2001-08-16 2008-12-01 Baxter International Inc. Formulaciones de microparticulas a base de propelentes.

Also Published As

Publication number Publication date
GEP20063917B (en) 2006-09-11
PL366911A1 (en) 2005-02-07
CN101045166A (zh) 2007-10-03
MA26185A1 (fr) 2004-07-01
IL158862A0 (en) 2004-05-12
JP2004535401A (ja) 2004-11-25
EP1395294A2 (en) 2004-03-10
HUP0400442A2 (hu) 2005-03-29
US20030118510A1 (en) 2003-06-26
WO2002094200A3 (en) 2003-02-20
LT2003107A (en) 2004-05-25
BG108494A (en) 2004-07-30
AR033903A1 (es) 2004-01-07
NO20035157D0 (no) 2003-11-20
OA13136A (en) 2006-12-13
YU98503A (sh) 2006-05-25
IL158862A (en) 2008-07-08
AP2003002918A0 (en) 2003-12-31
CN1314445C (zh) 2007-05-09
MXPA03010649A (es) 2005-10-05
WO2002094200A2 (en) 2002-11-28
EA007408B1 (ru) 2006-10-27
NZ529572A (en) 2006-02-24
US20050152848A1 (en) 2005-07-14
US6890518B2 (en) 2005-05-10
AP1763A (en) 2007-08-02
HRP20030949A2 (en) 2005-04-30
TNSN03116A1 (en) 2005-12-23
ZA200309085B (en) 2004-11-22
SK15532003A3 (sk) 2004-06-08
LT5153B (lt) 2004-08-25
EA200301222A1 (ru) 2004-08-26
ECSP034855A (es) 2004-03-23
CN1582171A (zh) 2005-02-16
TR200400295T2 (tr) 2005-04-21
CA2447236A1 (en) 2002-11-28
US20030216542A1 (en) 2003-11-20
LV13197B (en) 2004-10-20
MY137181A (en) 2009-01-30
US6838076B2 (en) 2005-01-04
AU2002303869B2 (en) 2007-08-16
EP1395294A4 (en) 2006-01-11
CZ20033182A3 (cs) 2004-09-15
KR20030097876A (ko) 2003-12-31
CO5540371A2 (es) 2005-07-29
BR0209896A (pt) 2004-08-17

Similar Documents

Publication Publication Date Title
IS7043A (is) Lyfjagjöf efnafræðilega umbreytts insúlíns í lungu
DK3210637T3 (da) Infusionssæt
DK1383560T4 (da) Infusionssæt
EP1438086A4 (en) NOSE NEEDLE
ATE319666T1 (de) Gipszusammensetzung mit verbesserter deformationsstabilität
DE60115418D1 (de) Mikroinfusionsvorrichtung zur verabreichung von medikamenten
CY2009013I1 (el) Νεα χρηση μιας ενωσης πεπτιδικης κατηγοριας για τη θεραπεια του μη νευροπαθους φλεγμονωδους πονου
EE05020B1 (et) Glburiidi ravimkoostis
DE50209245D1 (de) Neuroprotektives medikament
ATE324883T1 (de) Pharmazeutische zusammensetzung enthaltend lumiracoxib
NO20034556L (no) Imidazotriazinon-holdige sammensetninger for nasal administrering
DE60203537D1 (de) 5ht1-rezeptoragonist enthaltendes arzneimittel
DE60231611D1 (de) Verabreichung von opioiden durch inhalation
DE60217390D1 (de) Bicalutamid enthaltende pharmazeutische zusammensetzung
IS7092A (is) Einfaldur skammtur af asíþrómýsíni til meðhöndlunar á sýkingum í öndunarvegi
MXPA03005980A (es) Composiciones para administracion nasal de insulina.
PL367639A1 (en) Novel heterocyclic compound and medicinal use thereof
DE10291905D2 (de) Pharmazeutische Zusammensetzung
ATE350029T1 (de) Pharmazeutische zusammensetzung enthaltend gamma- butyrobetain
EE200300466A (et) Püridoindolooni derivaatide kasutamine ravimite valmistamiseks
ATA8202001A (de) Medikamentenapplikator
DE10107261B4 (de) Pharmazeutische Zusammensetzung
DE10295185D2 (de) Anästhesiespritze
DE60228703D1 (de) Verabreichung von sedativa-hypnotika durch inhalation
NO20040866L (no) Ny oral forlenget frigivelses doseringsform